论文部分内容阅读
目的:探讨早期应用肺表面活性物质预防早产儿呼吸窘迫综合征的疗效。方法:将68例呼吸窘迫综合征早产儿随机分为两组各34例,观察组于生后24 h内经气管插管内注入肺表面活性物质;对照组于出生24 h后气管插管内注入肺表面活性物质。观察两组患儿肺功能改善情况,对两组患儿住院天数、机械通气天数、用氧天数等方面进行比较。结果:经肺表面活性物质治疗后患儿的动脉氧分压(PaO2)、动脉血氧分压/吸入氧气浓度(PaO2/FiO2)、pH值及动脉二氧化碳分压(PaCO2)与用药前比较明显改善,差异有统计学意义(P<0.05);观察组各项指标与对照组比较改善明显,差异有统计学意义(P<0.05);观察组机械通气时间、用氧时间及住院时间与对照组比较明显缩短,差异有统计学意义(P<0.05)。结论:肺表面活性物质替代治疗能明显改善呼吸窘迫综合征早产儿的肺功能,且早期应用效果更好。
Objective: To explore the early use of pulmonary surfactant in the prevention of respiratory distress syndrome in premature infants. Methods: Sixty-eight premature infants with respiratory distress syndrome were randomly divided into two groups of 34 cases. The observation group received pulmonary intratracheal intratracheal intratracheal intratracheal intratracheal intratracheal injections within 24 hours after birth. The control group was injected intratracheal intubation 24 hours after birth Pulmonary surfactant. The improvement of pulmonary function in both groups was observed. The days of hospitalization, the days of mechanical ventilation and days of oxygen were compared between the two groups. Results: PaO2, PaO2 / FiO2, PaCO2 and PaCO2 in children after pulmonary surfactant treatment were significantly higher than those before treatment (P <0.05). The indicators in the observation group improved significantly compared with the control group, the difference was statistically significant (P <0.05); the observation group, mechanical ventilation time, oxygen time and hospital stay with the control Group was significantly shorter, the difference was statistically significant (P <0.05). CONCLUSIONS: Surfactant replacement therapy can significantly improve lung function in preterm infants with respiratory distress syndrome, and its early application is better.